Table 2.

Ferritin levels at start of anakinra (deemed day 1) and subsequent ferritin levels (on days 1–50 after start of anakinra) are summarized where available

	Patient	Survival	Months survival	Max ferritin response	Ferritin (ng/ml)
					Day 1	Day 5	Day 10	Day 15	Day 20	Day 25	Day 30	Day 35	Day 40	Day 45	Day 50
Primary hematologic malignant etiology	1	No	0.3	30%	109,988	76,905
	2	No	1.5	None	4338	5198	9011	10,524	11,071	9452	15,420	66,470	69,055
	3	No	1.8	96%	131,063	91,139	22,450	12,909	6337	10,281	8367	9372	5628	9337	19,069
	4	Yes	57	79%	11,897	3771	3322	2532							239
	5	No	0.2	20%	79,812	64,007
	6	No	0.2	None	39,812	53,100
	7	No	0.3	71%	133,511	79,803	39,206
Primary infectious etiology	8	No	0.3	None	10,287	291,504
	9	No	1.8	87%	144,361	75,034	79,258	57,126	18,072	28,319	33,511	58,730			103,881
	10	No	2.1	22%	4054	4604	4706	3167	6245	5121	10,463	4,395	8,216	16,821	10,367
	11	No	0.5	23%	36,291	67,904	37,206	28,099
Primary rheumatologic etiology	12	Yes	29	99%	28,911	19,006	4103	983		491					368
	13	Yes	59	99%	65,981	49,106	35,401	27,153	14,305	10,475		10,389	12,720		6137
	14	No	1.3	53%	1458	1385	1069	797	688	1222	1284	1965	1132
	15	Yes	4	88%	88,905	49,508	24,428	13,883	10,475	10,389			12,720
Other	16	Yes	49	72%	9346	7570	6606	5606	4879	3990	3395	3134	2534	2691	2595

Max ferritin response was determined by dividing maximum ferritin decrease after starting anakinra by ferritin level on day 1 of anakinra. A max ferritin response of “none” denotes that ferritin did not decrease after starting anakinra